Firms & Funds The Aspreva Effect: Canada’s life sciences snagged a healthy dose of VC last year. And the IPO of Aspreva Pharmaceuticals could spawn more. – Staff Writer - 1 June 2005 Share A- A+ 100% Create an account to continue reading Gain instant access to our expert editorial analysis and in-depth insight. Register for free Already have an account? Sign in
